Cargando…

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

In the past decade, a growing set of immunotherapies including immune checkpoint blockade, chimeric antigen receptor T cells, and bispecific antibodies propelled the advancement of oncology therapeutics. Accumulating evidence demonstrates that immunotherapy could eliminate tumors better than traditi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Ming, Jiao, Dechao, Qin, Shuang, Chu, Qian, Li, Anping, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242797/ https://www.ncbi.nlm.nih.gov/pubmed/31517538 http://dx.doi.org/10.1177/1534735419876351

Ejemplares similares

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma
por: Qin, Shuang, et al.
Publicado: (2020)

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
por: Li, Anping, et al.
Publicado: (2019)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis
por: Yi, Ming, et al.
Publicado: (2020)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
por: Lu, Yuting, et al.
Publicado: (2022)

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
por: Yan, Yuheng, et al.
Publicado: (2022)

Manipulating T-cell metabolism to enhance immunotherapy in solid tumor
por: Chen, Chen, et al.
Publicado: (2022)

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
por: Bai, Xianguang, et al.
Publicado: (2019)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer
por: Yu, Shengnan, et al.
Publicado: (2020)

Human Gut Microbiota: Dysbiosis and Manipulation
por: Shen, Dongqian, et al.
Publicado: (2012)

Gut Microbiota and Immunotherapy
por: Xu, Xiaoqing, et al.
Publicado: (2022)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017
por: Yi, Ming, et al.
Publicado: (2020)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021)

Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies
por: Quaranta, Gianluca, et al.
Publicado: (2022)

Retraction: Human gut microbiota: dysbiosis and manipulation
Publicado: (2013)

Gut Microbiota Manipulation in Irritable Bowel Syndrome
por: Mazzawi, Tarek
Publicado: (2022)

Exploiting innate immunity for cancer immunotherapy
por: Yi, Ming, et al.
Publicado: (2023)

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation
por: Qin, Shuang, et al.
Publicado: (2020)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

The Role of Gut Microbiota in Tumor Immunotherapy
por: Wu, Miao, et al.
Publicado: (2021)

Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
por: Li, Bolei, et al.
Publicado: (2021)

Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
por: Hou, Xinxin, et al.
Publicado: (2022)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

Manipulating the gut microbiota to maintain health and treat disease
por: Scott, Karen P., et al.
Publicado: (2015)

Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis
por: Zackular, Joseph P., et al.
Publicado: (2015)

Manipulation of Gut Microbiota Using Acacia Gum Polysaccharide
por: Rawi, Muhamad Hanif, et al.
Publicado: (2021)

The role of cancer-derived microRNAs in cancer immune escape
por: Yi, Ming, et al.
Publicado: (2020)

Gut microbiota and calcium balance
por: Wang, Jiali, et al.
Publicado: (2022)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Gut Microbiota and the Paradox of Cancer Immunotherapy
por: Poutahidis, Theofilos, et al.
Publicado: (2014)

Gut Microbiota and Immunotherapy for Alzheimer’s Disease
por: Dai, Chun-Ling, et al.
Publicado: (2022)

Association of gut microbiota composition and craniosynostosis
por: Fu, Zuqiang, et al.
Publicado: (2023)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_knes38uo4ntq54iqcmrqfvgqc6